Preclinical data reveal spectinamide's effectiveness in replacing linezolid in the Nix-TB regimen, suggesting a safer alternative for tuberculosis therapy.
Spectinamides have garnered interest as experimental tuberculosis therapeutics owing to their safety profile and efficacy as partner agents when used in conjunction with established regimens in mice. The Nix-TB regimen of bedaquiline, pretomanid, and linezolid represents a short, effective regimen recommended for treatment of pre-extensively drug-resistant tuberculosis. However, linezolid administration is associated with severe adverse events that limit its use. Here we present preclinical data comparing Nix-TB regimens anchored by either linezolid or spectinamide MBX-4888A.
No takes yet. Share an insight, caveat, or question.
Peroutka‐Bigus et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: